Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVBP ArriVent BioPharma	$20.04 -2.9%	$19.21	$15.47 ▼ $36.37	$685.63M	1.47	183,466 shs	302,038 shs
IMNM Immunome	$8.63 +0.3%	$7.59	$5.15 ▼ $16.81	$750.91M	2	918,176 shs	689,788 shs
INMB INmune Bio	$7.36 -3.8%	$7.58	$4.32 ▼ $10.50	$169.16M	1.63	262,805 shs	338,059 shs
RCKT Rocket Pharmaceuticals	$2.48 +6.4%	$6.56	$2.19 ▼ $26.98	$264.83M	1.02	1.81 million shs	20.90 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVBP ArriVent BioPharma	+1.13%	-1.10%	-0.91%	-15.38%	+7.22%
IMNM Immunome	+1.30%	+0.47%	+2.38%	-10.23%	-39.52%
INMB INmune Bio	+4.79%	-0.39%	-2.17%	-1.92%	-24.33%
RCKT Rocket Pharmaceuticals	-62.84%	-65.99%	-67.77%	-75.53%	-89.12%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AVBP ArriVent BioPharma	0.994 of 5 stars	3.6	0.0	0.0	2.2	0.0	0.0
IMNM Immunome	2.6208 of 5 stars	4.5	0.0	0.0	3.5	2.5	0.0
INMB INmune Bio	1.7532 of 5 stars	3.6	0.0	0.0	2.7	1.7	0.6
RCKT Rocket Pharmaceuticals	4.9146 of 5 stars	4.3	3.0	4.7	3.1	5.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVBP ArriVent BioPharma	3.14	Buy	$39.29	96.04% Upside
IMNM Immunome	3.00	Buy	$23.33	170.37% Upside
INMB INmune Bio	3.17	Buy	$22.80	209.78% Upside
RCKT Rocket Pharmaceuticals	2.47	Hold	$22.46	805.71% Upside

Current Analyst Ratings Breakdown

Latest INMB, IMNM, RCKT, and AVBP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/28/2025	RCKT Rocket Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
5/28/2025	RCKT Rocket Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$32.00 ➝ $9.00
5/28/2025	RCKT Rocket Pharmaceuticals	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$51.00 ➝ $19.00
5/28/2025	RCKT Rocket Pharmaceuticals	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Sell
5/28/2025	RCKT Rocket Pharmaceuticals	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$37.00 ➝ $8.00
5/28/2025	RCKT Rocket Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$7.00
5/28/2025	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$46.00 ➝ $17.00
5/28/2025	RCKT Rocket Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/27/2025	RCKT Rocket Pharmaceuticals	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold
5/20/2025	AVBP ArriVent BioPharma	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$40.00

(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	($4.79) per share	N/A
IMNM Immunome	$10.94M	68.65	N/A	N/A	$2.77 per share	3.12
INMB INmune Bio	$50K	3,383.24	N/A	N/A	$2.07 per share	3.56
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$5.46 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVBP ArriVent BioPharma	-$69.33M	-$3.77	N/A	N/A	N/A	N/A	-43.89%	-29.67%	8/13/2025 (Estimated)
IMNM Immunome	-$106.81M	-$3.18	N/A	N/A	N/A	-3,014.59%	-48.63%	-41.62%	8/11/2025 (Estimated)
INMB INmune Bio	-$30.01M	-$1.93	N/A	N/A	N/A	N/A	-117.48%	-78.96%	8/7/2025 (Estimated)
RCKT Rocket Pharmaceuticals	-$245.60M	-$2.63	N/A	N/A	N/A	N/A	-62.62%	-54.17%	8/4/2025 (Estimated)

Latest INMB, IMNM, RCKT, and AVBP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.58	-$0.56	+$0.02	N/A	N/A	N/A
5/12/2025	Q1 2025	AVBP ArriVent BioPharma	-$0.66	-$1.90	-$1.24	-$1.90	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/8/2025	Q1 2025	INMB INmune Bio	-$0.43	-$0.43	N/A	-$0.43	N/A	$0.05 million
5/5/2025	Q1 2025	RCKT Rocket Pharmaceuticals	-$0.59	-$0.56	+$0.03	-$0.56	$0.80 million	N/A
3/27/2025	Q4 2024	INMB INmune Bio	-$0.54	-$0.40	+$0.14	-$0.40	N/A	N/A
3/19/2025	Q4 2024	IMNM Immunome	-$0.68	-$0.84	-$0.16	-$1.28	$3.07 million	$2.74 million
3/3/2025	Q4 2024	AVBP ArriVent BioPharma	-$0.78	-$0.60	+$0.18	-$0.61	N/A	N/A
3/3/2025	Q4 2024	RCKT Rocket Pharmaceuticals	-$0.68	-$0.62	+$0.06	-$0.62	$0.03 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVBP ArriVent BioPharma	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVBP ArriVent BioPharma	N/A	19.28	19.28
IMNM Immunome	N/A	6.17	6.17
INMB INmune Bio	N/A	2.59	2.59
RCKT Rocket Pharmaceuticals	0.06	6.05	6.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVBP ArriVent BioPharma	9.48%
IMNM Immunome	44.58%
INMB INmune Bio	12.72%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
AVBP ArriVent BioPharma	N/A
IMNM Immunome	8.60%
INMB INmune Bio	35.20%
RCKT Rocket Pharmaceuticals	24.76%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVBP ArriVent BioPharma	40	34.21 million	N/A	N/A
IMNM Immunome	40	87.01 million	72.92 million	Optionable
INMB INmune Bio	10	22.98 million	14.37 million	Optionable
RCKT Rocket Pharmaceuticals	240	106.79 million	65.18 million	Optionable

INMB, IMNM, RCKT, and AVBP Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Rocket Pharmaceuticals, Inc. - RCKT

May 28 at 6:25 PM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Rocket Pharmaceuticals, Inc. (RCKT) And Encourages Stockholders to Connect

May 28 at 3:15 PM | accessnewswire.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Cut to "Hold" at TD Cowen

May 28 at 12:18 PM | marketbeat.com

RCKT Stock Tanks on Patient Death in Danon Disease Study

May 28 at 12:11 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Rating Lowered by Needham & Company LLC

May 28 at 11:29 AM | marketbeat.com

These Analysts Slash Their Forecasts On Rocket Pharmaceuticals

May 28 at 10:41 AM | benzinga.com

Rocket Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RCKT)

May 28 at 10:38 AM | marketbeat.com

US FDA places clinical hold on Rocket Pharma's gene therapy phase 2 trial of RP-A501 to treat Danon disease

May 28 at 5:39 AM | pharmabiz.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Receives "Hold" Rating from TD Cowen

May 28 at 2:41 AM | americanbankingnews.com

Investors Purchase High Volume of Rocket Pharmaceuticals Call Options (NASDAQ:RCKT)

May 28 at 1:06 AM | americanbankingnews.com

Rocket Pharmaceuticals, Inc. (RCKT) Gene Therapy Trial Paused Following Patient Death

May 27 at 9:28 PM | insidermonkey.com

Danon Disease Patient Dies in Rocket Gene Therapy Trial

May 27 at 7:37 PM | genengnews.com

Rocket Pharma Reports Patient Death In Rare Disease Gene Therapy Trial, FDA Puts Clinical Hold

May 27 at 12:00 PM | benzinga.com

Rocket Pharmaceuticals shares plunge after FDA halts key gene therapy trial following patient death

May 27 at 10:37 AM | proactiveinvestors.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Shares Down 5.6% - Time to Sell?

May 25 at 4:25 PM | marketbeat.com

Woodline Partners LP Increases Stock Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 25 at 4:41 AM | marketbeat.com

Toronto Dominion Bank Purchases Shares of 1,100,000 Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 22, 2025 | marketbeat.com

271,659 Shares in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Purchased by Soleus Capital Management L.P.

May 21, 2025 | marketbeat.com

Northern Trust Corp Has $8.34 Million Holdings in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 21, 2025 | marketbeat.com

Tema Etfs LLC Invests $1.14 Million in Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 20, 2025 | marketbeat.com

Point72 Asset Management L.P. Purchases 1,521,727 Shares of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT)

May 20, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INMB, IMNM, RCKT, and AVBP Company Descriptions

ArriVent BioPharma NASDAQ:AVBP

$20.04 -0.59 (-2.86%)

Closing price 04:00 PM Eastern

Extended Trading

$20.04 0.00 (0.00%)

As of 04:13 PM Eastern

ArriVent BioPharma, Inc. operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors. In addition, the company develops Furmonertinib, a third-generation tyrosine kinase inhibitor that is in multiple clinical trials across a range of epidermal growth factor receptor mutations (EFGRm) in non-small cell lung cancer (NSCLC), including a phase 3 clinical trial for treatment of patients with metastatic EFGRm NSCLC; phase 1b clinical trial for treatment of patients with NSCLC with other EGFR mutations and NSCLC with HER2 Exon 20 insertion mutations; and ARR-002. It has strategic collaborations with Aarvik Therapeutics Inc. to discover and develop antibody drug conjugates (ADCs) with improved activity and safety over single target bivalent ADCs; and Shanghai Allist Pharmaceuticals Co., Ltd. to develop and commercialize Furmonertinib. The company was incorporated in 2021 and is based in Newtown Square, Pennsylvania.

Immunome NASDAQ:IMNM

$8.63 +0.03 (+0.35%)

Closing price 04:00 PM Eastern

Extended Trading

$8.64 +0.01 (+0.12%)

As of 06:52 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

INmune Bio NASDAQ:INMB

$7.36 -0.29 (-3.79%)

Closing price 04:00 PM Eastern

Extended Trading

$7.51 +0.15 (+2.09%)

As of 06:50 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Rocket Pharmaceuticals NASDAQ:RCKT

$2.48 +0.15 (+6.44%)

Closing price 04:00 PM Eastern

Extended Trading

$2.46 -0.02 (-0.60%)

As of 06:50 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time